title: Dual receptors and distinct pathways mediate interleukin-1 receptor-associated kinase degradation in response to lipopolysaccharide. Involvement of CD14/TLR4, CR3, and phosphatidylinositol 3-kinase.
abstract: Lipopolysaccharide (LPS) signaling leading to nuclear factor-kappaB activation in mononuclear phagocytes involves interleukin-1 receptor-associated kinase (IRAK), which is rapidly activated after exposure to agonist. Although it is known that IRAK also undergoes rapid inactivation/degradation in response to LPS, providing negative feedback leading to LPS tolerance, mechanisms governing IRAK degradation are not fully understood. In the present study, examination of LPS signaling showed that IRAK degradation was bimodal and involved dual receptors and distinct pathways. Rapid degradation of IRAK, occurring within 30 min of exposure to agonist, was shown to signal through CD14/TLR4 and was regulated by phosphatidylinositol 3-kinase. A second delayed wave of IRAK degradation occurred 2 h after exposure to LPS and was mediated by CR3 independently of phosphatidylinositol 3-kinase. Thus, multiple independent mechanisms have evolved to regulate IRAK degradation, likely reflecting the importance of limiting cellular responses to LPS. Recognition of a CR3-dependent, CD14/TLR4-independent pathway leading to IRAK degradation has implications for understanding modulation of LPS responses by cells with important immunoregulatory function such as dendritic cells that are CD14(-).
authors.affiliation: Department of Medicine, Division of Infectious Diseases, University of British Columbia Faculties of Medicine and Science, British Columbia, Canada.
authors.forename: Sanaâ
authors.initials: S
authors.lastname: Noubir
authors.forename: Zakaria
authors.initials: Z
authors.lastname: Hmama
authors.forename: Neil E
authors.initials: NE
authors.lastname: Reiner
mesh_terms: D002460:Cell Line; D006801:Humans; D053592:Interleukin-1 Receptor-Associated Kinases; D018950:Lipopolysaccharide Receptors / Q000032:analysis / Q000502:physiology*; D008070:Lipopolysaccharides / Q000494:pharmacology*; D016177:Macrophage-1 Antigen / Q000032:analysis / Q000502:physiology*; D008562:Membrane Glycoproteins / Q000502:physiology*; D019869:Phosphatidylinositol 3-Kinases / Q000502:physiology*; D011493:Protein Kinase C / Q000502:physiology; D011494:Protein Kinases / Q000378:metabolism*; D011956:Receptors, Cell Surface / Q000502:physiology*; D051197:Toll-Like Receptor 4; D051193:Toll-Like Receptors; D000099221:Protein Kinase C zeta
chemical_list: D053592:Interleukin-1 Receptor-Associated Kinases; D018950:Lipopolysaccharide Receptors; D008070:Lipopolysaccharides; D016177:Macrophage-1 Antigen; D008562:Membrane Glycoproteins; D019869:Phosphatidylinositol 3-Kinases; D011493:Protein Kinase C; D011494:Protein Kinases; D011956:Receptors, Cell Surface; D051197:Toll-Like Receptor 4; D051193:Toll-Like Receptors; D000099221:Protein Kinase C zeta; C495345:TLR4 protein, human